Medigene AG MDGEF
Set alert
At close · May 14
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 2.59
- Prev close
- 2.59
- Mkt cap
- 38.17M
- Vol
- 10.00K
- Avg vol
- 5.71K
- EPS
- -1.28
- P/E
- -2.02
More statistics
- Low
- 0.10
- High
- 2.59
News
1 year ago globenewswire.com
Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided…
1 year ago globenewswire.com
Medigene AG announces closing of its first SEPA tranche
Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
1 year ago globenewswire.com
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
1 year ago globenewswire.com
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
2 years ago globenewswire.com
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
2 years ago globenewswire.com
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
2 years ago globenewswire.com
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1 Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried, August…
2 years ago seekingalpha.com
Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript
Medigene AG (OTCPK:MDGEF) Q2 2024 Earnings Conference Call August 14, 2024 9:30 AM ET Company Participants Pamela Keck - Head, IR Selwyn Ho - CEO Conference Call Participants Joe Pantginis - H.C.…
2 years ago globenewswire.com
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
Significant corporate and scientific progress in the first half of 2024 Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024 New additions to End-to-End…
2 years ago globenewswire.com
Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor…
2 years ago prnewswire.com
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary…
2 years ago globenewswire.com
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design…
2 years ago globenewswire.com
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
2 years ago globenewswire.com
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
2 years ago globenewswire.com
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated…
2 years ago globenewswire.com
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene's financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q…
2 years ago globenewswire.com
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
2 years ago globenewswire.com
Medigene AG reports Financial Results and Business Update for Q1 2024
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell…
2 years ago globenewswire.com
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for…
2 years ago seekingalpha.com
Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript
Medigene AG (MDGEF) Full Year 2023 Earnings Call Transcript
-
10 years ago benzinga.com
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy